Antares Pharma, Inc. Announces First Shipment of Commercial VIBEX™ Auto-Injector Devices to Teva Pharmaceutical Industries Limited

Published: Apr 03, 2013

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the first shipment of commercial-ready VIBEX™ auto-injector devices to Teva at the end of the first quarter 2013. This initial order for pre-launch quantities of the generic epinephrine auto-injector represents the first of many shipments that will take place during 2013. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “Today’s announcement marks yet another milestone for Antares and the successful commercial production of VIBEX™ devices is an important achievement.” Dr. Wotton continued, “Our growing and maturing development pipeline that includes OTREXUP™ for Rheumatoid Arthritis and QST for testosterone replacement therapy, is constructed around the proprietary VIBEX™ platform and this demonstrated ability to manufacture devices at a commercial scale is both a significant accomplishment for the Company and a major step forward for our own internal development programs.”

Back to news